<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Trakakis, E.</style></author><author><style face="normal" font="default" size="100%">Chryssikopoulos, A.</style></author><author><style face="normal" font="default" size="100%">Phocas, I.</style></author><author><style face="normal" font="default" size="100%">Sarandakou, A.</style></author><author><style face="normal" font="default" size="100%">Rizos, D.</style></author><author><style face="normal" font="default" size="100%">Stavropoulos-Giokas, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The incidence of 21α-hydroxylase deficiency in Greek hyperandrogenic women: Screening and diagnosis</style></title><secondary-title><style face="normal" font="default" size="100%">Gynecological Endocrinology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">17-Hydroxyprogesterone</style></keyword><keyword><style  face="normal" font="default" size="100%">21α-hydroxylase</style></keyword><keyword><style  face="normal" font="default" size="100%">HLA antigens</style></keyword><keyword><style  face="normal" font="default" size="100%">Hyperandrogenic women</style></keyword><keyword><style  face="normal" font="default" size="100%">NC-CAH</style></keyword><keyword><style  face="normal" font="default" size="100%">Screening</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">1998</style></year><pub-dates><date><style  face="normal" font="default" size="100%">1998///</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">12</style></volume><pages><style face="normal" font="default" size="100%">89 - 96</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The purpose of this prospective study was to determine the incidence of any form of 21α-hydroxylase deficiency among Greek women with hyperandrogenic symptoms, and to test the predictive value of basal serum 17-hydroxyprogesterone (17-OHP) in the early follicular phase as a screening index for patient preselection to adrenocorticotropic hormone (ACTH) testing. Eighty-eight unselected women with hyperandrogenic symptoms were examined in the Gynecological Endocrinology Unit of the Second Department of Obstetrics and Gynecology of Athens University. Using the ACTH-stimulated 17-OHP values at 60 minutes (17-OHP60) the study population was divided into four groups (A, B, C and D). Clinical and basal hormonal parameters as well as serum 17-OHP60 values and human leukocyte antigens were studied. Both clinical and basal hormonal parameters could be used to distinguish only patients with severe 21α-hydroxylase deficiency (group A). In contrast, patients with moderate non-classical congenital adrenal hyperplasia (NC-CAH; group B), heterozygotes for NC-CAH (group C), and unaffected females (group D) can be diagnosed and classified only by serum 17-OHP60 values. In conclusion, the incidence of NC-CAH in Greek females with hyperandrogenic symptoms is 3.4%. The positive predictive value of basal 17-OHP is only 13% for this disease. Only 17-OHP60 helps to diagnose and classify moderate and mild forms of NC-CAH. Thus, it seems that ACTH testing is imperative in every subject suspected of this enzymatic disorder.</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue></record></records></xml>